Effects of Ketoconazole on the Proliferation and Cell Cycle of Human Cancer Cell Lines

Marie-Elisabeth Forgue-Lafitte, Anne-Marie Coudray, Dominique Fagot, and Jan Mester
Institut National de la Santé et de la Recherche Médicale, INSERM U 55, Centre de Recherches Paris-Saint-Antoine, Hôpital Saint-Antoine, 184 Faubourg Saint-Antoine, 75012 Paris, France

ABSTRACT

The growth-inhibitory effects of ketoconazole, an antifungal agent which inhibits arachidonic acid lipooxygenases and cytochrome P-450 enzymes, were tested in human colon and breast cancer cell lines. In the serum independent HT29-S-B6 colon cell clone, ketoconazole reduced cell proliferation and [3H]thymidine incorporation in a dose-dependent fashion, with a 50% inhibitory concentration of approximately 2.5 µM. Flow cytometry showed an accumulation of cells in the G0-G1 phase of the cell cycle and a concomitant decrease of the percentage of cells in S phase. Ketoconazole also inhibited [3H]thymidine incorporation in the hormone-independent breast cancer cells MDA-MB-231 and Evsa-T, with respective 50% inhibitory concentrations of approximately 13 and 2 µM. The mechanism of action of ketoconazole is unknown. However, another lipooxygenase inhibitor, BW755C, inhibited only weakly [3H]thymidine incorporation and accumulated the cells in S and G2. Conversely, clotrimazole and SKF525A, inhibitors of cytochrome P-450 enzymes, had effects similar to those of ketoconazole on HT29-S-B6 cell whereas metronidazole and secnidazole, other azole derivatives which do not inhibit cytochrome P-450 enzymes, had no effect. The results suggest that cytochrome P-450 enzyme(s) activity(ies) could be implicated in the antiproliferative effects of ketoconazole.

INTRODUCTION

Ketoconazole, an antifungal drug (1), blocks steroidogenesis (2) by inhibition of the cholesterol side chain cleavage (3) and has been used for this reason in the treatment of hormone-dependent prostate cancer (4, 5). Besides its indirect effect on hormone-dependent cancers, ketoconazole has been reported to inhibit hepatic metastasis from a human pancreatic adenocarcinoma in the nude mouse (6) and to reduce the incidence of pulmonary metastases in a mouse melanoma (7). In addition, ketoconazole has been found to exert a cytotoxic effect in various cancer cell lines [breast, colon, pancreas, prostate, and leukemia], as indicated by clonogenic assay in soft agar (8), and to potentiate the antitumor effect of interleukin 1α on murine RIF tumors [mainly by inhibiting the secretion of corticosterone (9)]. The mechanism of action of ketoconazole in the hormone-independent cell lines has not been elucidated. Ketoconazole inhibits the activities of cytochrome P-450 enzymes (2, 10, 11) and of arachidonic acid lipooxygenases (12) and has antiglucocorticoid properties (13); these processes may be indispensable for mitogenic signaling or for cell cycle progression.

In the work reported here, we have studied the effect of ketoconazole in three cell lines: (a) the clone HT29-S-B6, derived from the human colon adenocarcinoma cell line HT29, and able to proliferate and to be subcultured in a defined medium without exogenous growth factors (14); and (b) two (estrogen-independent) human breast cancer cell lines (Evsa-T and MDA-MB-231).

Received 6/8/92; accepted 10/2/92.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported by INSERM.

2 To whom requests for reprints should be addressed.

MATERIALS AND METHODS

Materials. Ketoconazole was from Sigma Chemical Co., St. Louis, MO; secnidazole and metronidazole were from Rhone-Poulenc, Vitry-sur-Seine, France; clotrimazole was from Laboratoires Roger Bellon, Neuilly-sur-Seine, France; SKF525A was from Smith, Kline and French Laboratories, Welwyn Garden, England; BW755C was from Wellcome Research Laboratories, Beckenham, England; and RU 38486 was from Roussel-UCLAF, Romainville, France. All other materials were of reagent grade.

Cell Culture. The subline HT29-S derived from HT29 cells and adapted to serum-free culture (14) was cloned by limiting dilution in the presence of serum. Clone B6, passages 5 to 30, was used throughout the present study. The HT29-S-B6 cells were maintained in Dulbecco’s modified Eagle’s medium: Ham F-12 nutrient mixture (50/50; Seromed, ATGC, Noisy-le-Grand, France), supplemented with 10 mM glucose, a final concentration of 4.5 g/liter, nonessential amino acids, and 15 µg/ml iron-saturated transferrin (Boehringer Mannheim, Mannheim, Germany), at 37°C in a humidified atmosphere of 5% CO2 in air. Stock cultures were passaged each week and the medium was changed every 1–2 days. Evsa-T and MDA-MB-231 cell lines were cultured in Dulbecco’s modified Eagle’s medium:Ham’s F12 medium (50/50) containing 5% fetal calf serum (Boehringer Mannheim). The BALB/c mouse 3T3 A3 fibroblasts were cultured in α-minimal essential medium (Gibco-BRL, Cergy-Pontoise, France) supplemented with 6% fetal calf serum.

Evaluation of the Rate of Cell Proliferation: Growth Curves, [3H]Thymidine Incorporation, and Flow Cytometry. HT29-S-B6 cells (5 x 10^5) were plated in 35-mm Petri dishes. The next day, the medium was changed and effectors were added in a small volume (10–20 µl). The incubation medium was renewed every day during the experiments. The same triplicate dishes were used for cell counts, [3H]thymidine incorporation, and flow cytometry. [3H]Thymidine (0.5 µCi) was allowed to incorporate for 24 h; at the end of incubation, cells were rinsed with 1 ml of medium, detached with 1 ml of trypsin-EDTA, and diluted (1:3) with a medium enriched with 6% fetal calf serum; IC50, 50% inhibitory concentration.
were selected and evaluated as percentages of the total by a graphic method (15).

Evsa-T and MDA-MB-231 cells were seeded in 24-well plates (20 x 10^4 cells in 1 ml medium/well). Ketoconazole was added 1 day later. [3H]Thymidine incorporation was evaluated every 24 h (2 μCi/ml during 2 h). At the end of the incubation, the medium was acidified with 1 M ascorbic acid. After 2 washes with 1 ml PBS, the cells were fixed with trichloroacetic acid (5%; 2 x1 ml) and solubilized in 0.1 N NaOH. Portions of the lysates were used for the determination of the incorporated 3H radioactivity and of the protein contents (by the Bio-Rad assay).

For the viability tests, the A31 cells were grown to confluence in 24-well plates in the complete (6% FCS-containing) medium, and the appropriate concentration of ketoconazole was added: the growth-arrested cells (16) were further incubated (with ketoconazole) for 48 h; the drug was removed thereafter, and the cells were stimulated with fresh medium containing 6% FCS and 2 μCi of [3H]thymidine/ml. After 24 h, the incubation was terminated by addition of ascorbic acid. The incorporated [3H]thymidine radioactivity was determined as for the breast cancer cells.

RESULTS

Effect of Ketoconazole on Cell Growth. Ketoconazole inhibited the proliferation of HT29-S-B6 cells in a dose-dependent manner. In the serum-free medium used for the continuous culture of these cells, a complete arrest of growth was observed after 48 h with 1 μM and after 24 h with 5-10 μM ketoconazole (Fig. 1A). At longer times and at higher concentrations, the decrease of the cell number could be attributed to cell death. Assuming that 100% inhibition corresponds to no increase in cell number during the incubation, the IC50 evaluated after 48 h was approximately 2.5 μM (Fig. 1B). The incorporation of tritiated thymidine in the control and treated cells after 24, 48, and 72 h of incubation was measured in the same experiments (Fig. 1C). A dose-dependent inhibition of [3H]thymidine incorporation was observed within the first 24 h of treatment with ketoconazole, suggesting that the drug rapidly inhibited the synthesis of DNA. After 3 days, [3H]thymidine incorporation was further lowered to 40% of control with 1 μM ketoconazole.

In the presence of serum (10% FCS), the dose-response curve was shifted to higher concentrations of ketoconazole (IC50 x 10 μM, evaluated after 48 h of treatment; data not shown).

Apart from the HT29 cells, we have also tested the effect of ketoconazole on the growth of two human mammary carcinoma cell lines (Fig. 2). The incorporation of [3H]thymidine in the Evsa-T cell line was strongly inhibited by ketoconazole (IC50 x 2 μM). In contrast, the MDA-MB-231 cell line was much less sensitive to ketoconazole; at low concentrations [1-5 μM], there was no significant inhibition of [3H]thymidine incorporation in these cells, and the IC50 was approximately 13 μM [evaluated after 48 h of culture (Fig. 2)]. The protein contents of the cell lysates confirmed the dose-dependent inhibition of cell proliferation by ketoconazole in both cell lines (not shown).

Effect of Ketoconazole on the Cell Cycle of HT29 Cells. The effect of ketoconazole on the cell cycle of HT29-S-B6 cells was determined by flow cytometry. The results obtained after treatment of cells for 24-72 h with 1-25 μM ketoconazole are shown in Fig. 3. Ketoconazole induced a dose-dependent decrease of the number of cells in S phase within 24 h of treatment (from 17 to 3%) and a corresponding increase of the percentage of cells in G0-G1 (from 64 to 80%). Some cells remained in G2 (17% after 24 h in the presence of 25 μM ketoconazole). The proportion of binucleated cells which sorted in the "G2" fraction by cytofluorography was evaluated by fluorescence microscopy after staining with propidium iodide. Only a small percentage (3-4%) of binucleated cells could be observed. The treatment by ketoconazole did not affect this proportion.
Fig. 2. Effect of ketoconazole on \(^{3}\text{H}\)thymidine incorporation in human breast cancer cell lines. Ewta-T (○) and MDA-MB-231 (○) cells were seeded in 24-well plates (20 × 10\(^3\) cells/well). After 1 day, ketoconazole was added in fresh medium at the concentrations indicated. The incorporation of \(^{3}\text{H}\)thymidine was evaluated between 22 and 24 h (not shown) and between 46 and 48 h in ketoconazole-treated and control cells. Data are means and ranges (bars) of triplicates.

The reversibility of the cell cycle arrest induced by ketoconazole was studied after removal of the drug following a 24- or 48-h treatment with 5 or 10 \(\mu\text{M}\) ketoconazole. Cytovironometric analysis showed that the cells reentered the cell cycle within 24 h upon removal of the drug and that the proportion of cells in S phase returned to control values (Fig. 4). Cells counts confirmed that HT29-S-B6 cells were able to resume their proliferation in such conditions (not shown).

Since a stationary phase could not be obtained in the cancer cells studied, the direct toxicity of ketoconazole was tested on density-arrested, quiescent (16) BALB/c 3T3 (clone A31) mouse fibroblasts. The preincubation of quiescent A31 cells with concentrations up to 20 \(\mu\text{M}\) during 48 h did not affect their viability or the resumption of the cell cycle upon the addition of fresh medium. Cellular toxicity occurred at 50 \(\mu\text{M}\) ketoconazole.

Effects of Other Inhibitors of Lipoxygenase and of Cytochrome P-450 Enzymes. We have measured the proliferation of HT29-S-B6 cells in the presence of several substituted azole derivatives currently used as antifungal or antibacterial agents (reviewed in Ref. 11). Clotrimazole was as potent as ketoconazole in inhibiting the proliferation of HT29-S-B6 cells; the IC\(_{50}\) of clotrimazole was approximately 2.5 \(\mu\text{M}\) after 48 h (Table 1). In addition, clotrimazole inhibited \(^{3}\text{H}\)thymidine incorporation by HT29-S-B6 cells in a dose-dependent manner (Table 1). Clotrimazole was more toxic than ketoconazole at high concentrations since virtually all cells were killed by a 24-h treatment with 25 \(\mu\text{M}\) clotrimazole and after 48 h with 10 \(\mu\text{M}\). Metronidazole and secnidazole, other azole derivatives which do not inhibit cytochrome P-450-dependent enzymes (11), had no growth-inhibitory activity (10–100 \(\mu\text{M}\)). On the other hand, SKF525A, another inhibitor of cytochrome P-450 enzymes (17), also inhibited cell proliferation and the percentage of cells in S phase in a dose-dependent manner, with an IC\(_{50}\) of approximately 4 \(\mu\text{g/ml}\) after 48 h (not shown).

Apart from its action on cytochrome P-450 enzymes, ketoconazole has also been reported as an inhibitor of arachidonic acid lipoxygenase and therefore of leukotriene synthesis (12). In addition, ketoconazole is also an inhibitor of glucocorticoid-receptor interactions (13). High concentrations (\(\geq 100 \mu\text{M}\) of another lipoxygenase inhibitor, BW755C (18), inhibited the proliferation of HT29-S-B6 cells (at 50 \(\mu\text{M}\), no effect of BW755C was obtained); 200 \(\mu\text{M}\) BW755C caused extensive cell death. However, in the presence of 100 \(\mu\text{M}\) BW755C, the incorporation of \(^{3}\text{H}\)thymidine was only weakly inhibited (71 and 78% of controls after 24 and 48 h of incubation, respectively). In addition, the cytofluorometry analysis of cells incubated with BW755C showed no accumulation in G\(_1\) but rather an accumulation of cells in late S and G\(_2\) (Fig. 5). The percentages of cells in G\(_1\), S, and G\(_2\) shifted from 70, 19, and 11, respectively (control) to 47, 20, and 33 in cells treated for 24 h with 100 \(\mu\text{M}\) BW755C.

The possible role of glucocorticoid receptors on the proliferation of HT29-S-B6 cells was also investigated. Neither dexamethasone (0.2–20 \(\mu\text{M}\)) nor the antiglucocorticoid drug RU 38486 (0.1–1 \(\mu\text{M}\)) had any effect on the proliferation of these cells (not shown).

DISCUSSION

In HT29-S-B6 human colon cancer cells, ketoconazole inhibited growth as well as \(^{3}\text{H}\)thymidine incorporation and the proportion of cells in S phase in a concentration-dependent manner. The effect of ketoconazole was observed in both the
Fig. 4. Reversibility of the effect of ketoconazole. HT29-S-B6 cells were seeded in 35-mm dishes and incubated in the absence (controls) or presence (5 μM or 10 μM) of ketoconazole. In a series of dishes, the drug was removed after 24 h and the cells were incubated for the following 24 h in a fresh medium. At the end of the incubations, the cells were harvested for flow cytometry analysis. The fluorescent profiles of DNA contents of cells are shown. The number of cells is represented as a function of fluorescence. The peak at left (fluorescence around 50) represents cells in G0-G1; the peak at right represents cells in G2-M. Cells in S phase are characterized by intermediate values of fluorescence. Cells treated for 24 h with 0 (a), 5 (b), or 10 (c) μM ketoconazole. Cells treated for 48 h with 0 (d), 5 (e), or 10 (f) μM ketoconazole. g, cells treated with 5 μM ketoconazole for 24 h and then allowed to recover in control medium. h, same protocol with 10 μM ketoconazole.

Table 1 Effect of clotrimazole on the proliferation and [3H]thymidine incorporation of HT29-S-B6 cells

<table>
<thead>
<tr>
<th>Clotrimazole (μM)</th>
<th>A. Cell no.</th>
<th>B. cpm</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>1.169 ± 0.024</td>
<td>2688 ± 333</td>
</tr>
<tr>
<td>0.5</td>
<td>1.124 ± 0.016</td>
<td>2249 ± 216</td>
</tr>
<tr>
<td>1</td>
<td>0.982 ± 0.046</td>
<td>2044 ± 301</td>
</tr>
<tr>
<td>2.5</td>
<td>0.807 ± 0.024</td>
<td>1081 ± 242</td>
</tr>
<tr>
<td>5</td>
<td>0.626 ± 0.032</td>
<td>647 ± 89</td>
</tr>
</tbody>
</table>

Fig. 5. Effect of BW755C on the cell cycle in the HT29-S-B6 cells. The cells were treated for 48 h with clotrimazole at the concentrations indicated and the number of cells were determined (data indicated in Column A as millions of cells); in the same dishes, [3H]thymidine was allowed to incorporate for the last 24 h of incubation with clotrimazole (data indicated in Column B). Means ± SD of triplicate determinations are indicated.

BW 755C (μM)

<table>
<thead>
<tr>
<th>0</th>
<th>100</th>
<th>200</th>
</tr>
</thead>
<tbody>
<tr>
<td>24h</td>
<td></td>
<td></td>
</tr>
<tr>
<td>48h</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
dexamethasone nor the antiglucocorticoid RU 38486 had any effect on HT29-S-B6 cell growth. We found that, apart from ketoconazole, two other inhibitors of cytochrome P-450 enzymes, clotrimazole and SKF525A, were able to inhibit cell proliferation. On the other hand, mebro- nidazole and secnidazole, which do not inhibit the cytochrome P-450 enzymes, were also without effect on the proliferation of HT29-S-B6 cells. All these observations suggest that ketoconazole may act by inhibiting cytochrome P-450-dependent enzyme activity(ies); however, the hypothesis must yet be confirmed, and the growth-related target of the action of ketoconazole remains unknown at present. In rat mesangial cell cultures, it has been suggested that the inhibition of growth and expression of early cell cycle-related genes by ketoconazole and SKF525A may be related to a novel pathway of arachidonic acid metabolism involving cytochrome P-450 arachidonate monoxygenase (20). Such a pathway has not yet been evidenced in colon or breast cancer epithelial cells. Another target of ketoconazole is the sterol synthesis pathway (3). In this context, it is interesting that the inhibition of mevalonate synthesis by lovastatin (an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, the rate-limiting enzyme in the sterol biosynthetic pathway) apparently blocks cells in G1 by a mechanism (unknown) which does not involve the inhibition of cholesterol synthesis (21). Arrest of a minor portion of cells in G2 has also been observed with lovastatin (22), similar to that with ketoconazole (Figs. 3 and 4). Interestingly, lovastatin is a substrate of cytochrome P-450 3A (23) and a competitive inhibitor of this enzyme.

Growth arrest leads eventually to death of cancer cells, in contrast with normal cells which can become quiescent. The use of ketoconazole in the treatment of cancer is at present restricted to endocrine manipulation of hormone-dependent tumors. However, in an earlier study (5) the clinical response appeared to be better than would be expected from the decrease in serum testosterone levels. In addition, ketoconazole inhibited spontaneous metastasis in the B16-F10 melanoma tumor model (7) and the formation of metastatic colonies of a human pancreatic adenocarcinoma in the nude mouse (6). The elucidation of the mechanism of action of ketoconazole in the inhibition of cell growth may help to design efficient and, hopefully, less toxic antitumor drugs, especially in the chemotherapy-resistant colon cancer.

ACKNOWLEDGMENTS

We thank M. Kornprobst (INSERM U181) for performing the cyto-
fluorometry studies and Dr. G. Rosselin for constant support and help-
ful comments about the manuscript. We are indebted to Dr. Patrick
Maurel, INSERM U128, Montpellier, France, for helpful discussions
and for making available unpublished results. We thank Y. Issoulié
for photography.

REFERENCES

1. Graybill, J. R., and Drutz, D. J. Ketoconazole: a major innovation for treat-

Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450


4. Trachtenberg, J. Ketoconazole therapy in advanced prostatic cancer. J. Urol.,

5. Heyns, W., Drochmans, A., van der Schueren, E., and Verhoeven, G. Endo-
crine effects of high-dose ketoconazole therapy in advanced prostatic cancer.

6. Yilmazkikin, G. N., Agarwal, K. C., and Vezziridis, M. P. Inhibition of hepatic
metastasis from a human pancreatic adenocarcinoma (RWP-2) in the nude
mouse by prostatycin, forskolin, and ketoconazole. Cancer (Phila.), 65: 446–

7. Smith, P. A., Slotman, G. J., and Vezziridis, M. P. Ketoconazole: a chromo-
bboxane synthetase and 5-lipoxygenase inhibitor with antimitastatic activity

Cytotoxicity of ketoconazole in malignant cell lines. Cancer Chemother.

9. Braunschweiger, P. G., Kumar, N., Constantinidis, I., Wehrle, J., Glickson,
J. D., Johnson, C. S., and Furmanski, P. Potentiation of interleukin 1β-
mediated antitumor effects by ketoconazole. Cancer Res., 50: 4799–4771,
1990.

10. Capdevila, J., Gil, L., Orellana, M., Marnett, L. J., Mason, J. I., Yadagiri, P.,
and Falick, J. R. Inhibitors of cytochrome P-450-dependent arachidonic acid

11. Maurice, M., Pichard, L., Drujat, M., Fabric, J., Joyeux, H., Domerge, J.,
and Maurel, P. Effects of imidazole derivatives on cytochrome P-450 from

12. Beetsens, J. R., Loos, W., Somers, Y., Coene, M. C., and De Klerck, F.
Ketoconazole inhibits the biosynthesis of leukotrienes in vitro and in vivo.

13. Loose, D. S., Stover, E. P., and Feldman, D. Ketoconazole binds to gluco-
corticoid receptors and exhibits glucocorticoid antagonist activity in cultured

14. Forgue-Lafitte, M. E., Coudray, A. M., Briant, B., and Mester, J. Proliferation
of the human colon carcinoma cell line HT29: autocrine growth and deregulated
expression of the c-myc oncogene. Cancer Res., 49: 6566–6571,
1989.

15. Baisch, H., Goede, W., and Linden, W. Analysis of PCP data to determine the
fraction of cells in various phases of the cell cycle. Radiat. Environ.

growth factor (EGF) is required only during the traverse of early G1 in
PDGF-stimulated density-arrested Balb/c-3T3 cells. Exp. Cell Res., 147:


18. Higgs, G. A., Fower, R. J., and Vane, J. R. A new approach to antiinflam-

19. Buttle, T. M., and Chapman, S. W. Inhibition by ketoconazole of mitogen-
induced DNA synthesis and cholesterol biosynthesis in lymphocytes. Anti-

Endogenous non-cyclooxygenase metabolites of arachidonic acid modulate
growth and mRNA levels of immediate-early response genes in rat mesangial

21. Keyomarsi, K., Sando, L., Band, Y., and Pardoe, A. B. Synchronization of
tumor and normal cells from G1 to multiple cell cycles by lovastatin. Cancer

22. Jakobisiak, M., Bruna, S., Skierski, J. S., and Darzykyniekiz, Z. Cell cycle-
specific effects of lovastatin. Proc. Natl. Acad. Sci. USA, 88: 3628–3632,

23. Wang, R. W., Kari, P. H., Lu, A. Y. H., Thomas, P. E., Guengerich, F. P.,
and Vyas, K. P. Biotransformation of lovastatin. IV. Identification of cyto-
chrome P450 3A proteins as the major enzymes responsible for the metabo-
лизm of lovastatin in rat and human liver microsomes. Arch. Biochem.

4 L. Pichard and P. Maurel, personal communication.
Effects of Ketoconazole on the Proliferation and Cell Cycle of Human Cancer Cell Lines

Marie-Elisabeth Forgue-Lafitte, Anne-Marie Coudray, Dominique Fagot, et al.


Updated version

Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/52/24/6827

E-mail alerts

Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions

To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions

To request permission to re-use all or part of this article, use this link http://cancerres.aacrjournals.org/content/52/24/6827. Click on "Request Permissions" which will take you to the Copyright Clearance Center’s (CCC) Rightslink site.